Neonatal therapy after maternal central neurotropic drug exposure – a retrospective cohort study

Abstract

Abstract Objective: Evaluation of neonatal morbidity after maternal central neurotropic drug exposure. Design/Setting: Retrospective single-center level-III neonatology cohort analysis of neonates after CND from 2018 to 2021. Control group of neonates born to mothers without CND. Results: Significantly more frequent therapy need of neonates with CND [OR 11 (95% CI: 4.8-25); RR 7 (95% CI: 3.4-14); p<0.01]. Neonates after CND had lower Apgar-scores LM 1 [CND 8.1; CG 8.6; p=0.04]; LM 5 [CND 9; CG 9.7; p<0.01]; LM 10 [CND 9.6; CG 9.9: p=0.01]). The first symptom occurred in 95.35% within 24 h (mean: 3.3 h). CND group showed significantly more often preterm delivery [OR 3.5; RR 3.2; p<0.05], and especially cumulative multiple symptoms [OR 9.4; RR 6.6; p<0.01] but no correlation to multiple maternal medication use (p=0.3). Conclusion: Neonates exposed to CND are at increased risk for postnatal therapy, often due to multiple symptoms. Neonates should be monitored for 24h.